NeuroPace (NPCE)
(Real Time Quote from BATS)
$6.25 USD
-0.14 (-2.19%)
Updated Oct 18, 2024 11:36 AM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
NPCE 6.25 -0.14(-2.19%)
Will NPCE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NPCE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NPCE
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates
NPCE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates
Waters (WAT) Q2 Earnings and Revenues Top Estimates
Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates
Other News for NPCE
KCK LTD. Reduces Stake in NeuroPace Inc
NeuroPace (NPCE) Gets a Buy from Lake Street
NeuroPace Strengthens Management Team with Two Key Appointments
NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences
NeuroPace to Participate in Upcoming Healthcare Conferences in September